Maciej Jablkowski

Head

Medical University of Lodz

Poland

Research Interests

Explore related searches

Professors in Poland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Maciej Jablkowski is the Head at the Medical University of Lodz in Poland. His research areas include hepatology, diabetes, and COVID-19, with recent articles focusing on topics such as digit ratios in relation to COVID-19 severity and the cardiovascular risk profile in chronic hepatitis B patients. He has also investigated the efficacy of tenofovir alafenamide in hepatitis treatment and markers of insulin resistance associated with non-alcoholic fatty liver disease.

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Collaborators (10)

Renata Krupa

Lodz University of Technology

POLAND

View details

Aleksandra Araszkiewicz

Poznan University of Medical Sciences

POLAND

View details

Yoon Jun Kim

Professor

Seoul National University College of Medicine

SOUTH KOREA

View details

Marcin Kosmalski

Medical University of Lodz

POLAND

View details

Piotr Czarny

Medical University of Lodz

POLAND

View details

Angelica Lindén Hirschberg

Professor, MD, PhD

Karolinska Institutet

SWEDEN

View details

Hie-Won Hann

Thomas Jefferson University Hospital

UNITED STATES

View details

Janusz Szemraj

Medical University of Lodz

POLAND

View details

Anna Kasielska-Trojan

Medical University of Lodz

POLAND

View details

Bogusław Antoszewski

POLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Maciej Jablkowski

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Digit ratios and hospitalization for COVID-19: A test of the low-androgen-driven and high-androgen-driven theories of COVID-19 severity

Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks

Controlled attenuation parameter for the assessment of fatty liver in patients with type 1 diabetes mellitus: which cutoffs to choose?

Eight-year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials

Single-Nucleotide Polymorphisms in Base-Excision Repair-Related Genes Involved in the Risk of an Occurrence of Non-Alcoholic Fatty Liver Disease

Indirect insulin resistance markers are associated with nonalcoholic fatty liver disease in type 1 diabetes.

Long-term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety

Digit ratios and their asymmetries as risk factors of developmental instability and hospitalization for COVID‑19

Right–left digit ratios, a novel form of asymmetry: Patterns of instability in children and relationships to platelet counts and hospitalization in adults with COVID-19

MicroRNA profile and iron-related gene expression in hepatitis C-related hepatocellular carcinoma: a preliminary study

Collaborators (10)

Renata Krupa

Aleksandra Araszkiewicz

Yoon Jun Kim

Marcin Kosmalski

Piotr Czarny

Angelica Lindén Hirschberg

Hie-Won Hann

Janusz Szemraj

Anna Kasielska-Trojan

Bogusław Antoszewski

Make your next move.